Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for APGE
| Stock Name | Apogee Therapeutics, Inc. Common Stock |
| Ticker | APGE(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
Show aggregate APGE holdings
News associated with APGE
- Analysts Set Apogee Therapeutics Inc. (NASDAQ:APGE) PT at $97.29
- Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) has received an average rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts […] - 2025-09-02 03:06:53
- XTX Topco Ltd Raises Stock Holdings in Apogee Therapeutics Inc. (NASDAQ:APGE)
- XTX Topco Ltd raised its position in Apogee Therapeutics Inc. (NASDAQ:APGE – Free Report) by 170.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,188 shares of the company’s stock after buying an additional 10,840 shares during the quarter. […] - 2025-08-06 05:16:59
- Apogee Therapeutics Inc. (NASDAQ:APGE) Receives $99.00 Average Price Target from Brokerages
- Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year […] - 2025-07-14 02:22:47
- Apogee Therapeutics Sees Unusually High Options Volume (NASDAQ:APGE)
- Apogee Therapeutics Inc. (NASDAQ:APGE – Get Free Report) saw unusually large options trading activity on Monday. Traders acquired 3,810 put options on the company. This represents an increase of 728% compared to the average daily volume of 460 put options. Insiders Place Their Bets In related news, insider Carl Dambkowski sold 10,090 shares of the […] - 2025-07-09 02:50:45
- Financial Review: Apogee Therapeutics (NASDAQ:APGE) vs. argenx (NASDAQ:ARGX)
- argenx (NASDAQ:ARGX – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk. Profitability This table compares argenx and Apogee Therapeutics’ net […] - 2025-06-17 02:49:06
- Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Rating of “Buy” from Brokerages
- Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average rating of “Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is […] - 2025-06-16 04:11:05
- Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by Squarepoint Ops LLC
- Squarepoint Ops LLC raised its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 90.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,344 shares of the company’s stock after acquiring an additional 17,301 shares during the […] - 2025-05-30 05:34:59
- Millennium Management LLC Has $5.90 Million Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)
- Millennium Management LLC boosted its position in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 44.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 130,171 shares of the company’s stock after purchasing an additional 40,162 shares during the period. Millennium Management LLC’s holdings in Apogee Therapeutics were […] - 2025-05-28 04:56:52
- Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $94.60 Consensus PT from Analysts
- Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have received an average rating of “Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in […] - 2025-05-27 05:56:59
- ProShare Advisors LLC Increases Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)
- ProShare Advisors LLC grew its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 30.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,805 shares of the company’s stock after purchasing an additional 2,985 shares […] - 2025-05-26 05:18:49
- We Did The Math SMLF Can Go To $77
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-06 08:38:07
- Analyzing Apogee Therapeutics (NASDAQ:APGE) and Zura Bio (NASDAQ:ZURA)
- Zura Bio (NASDAQ:ZURA – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership. Profitability This table compares Zura Bio and […] - 2025-05-06 02:30:46
- Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $92.17
- Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average recommendation of “Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock in the […] - 2025-04-21 02:14:46
- KLP Kapitalforvaltning AS Acquires Shares of 5,000 Apogee Therapeutics, Inc. (NASDAQ:APGE)
- KLP Kapitalforvaltning AS bought a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,000 shares of the company’s stock, valued at approximately $226,000. Other large investors have also recently made changes to their […] - 2025-04-08 04:32:50
- Apogee Therapeutics, Inc. (NASDAQ:APGE) Position Reduced by Bank of New York Mellon Corp
- Bank of New York Mellon Corp lowered its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 1.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 110,827 shares of the company’s stock after selling 1,774 shares during the period. Bank of New York Mellon Corp’s holdings in Apogee Therapeutics were worth $5,020,000 […] - 2025-03-18 05:09:01
- Apogee Therapeutics (NASDAQ:APGE) Now Covered by Citigroup
- Citigroup began coverage on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $95.00 target price on the stock. A number of other brokerages have also recently issued reports on APGE. Canaccord Genuity Group assumed coverage on Apogee […] - 2025-03-14 05:48:55
- Apogee Therapeutics (NASDAQ:APGE) Earns Outperform Rating from Wedbush
- Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note issued to investors on Tuesday morning,RTT News reports. The firm currently has a $90.00 price objective on the stock. Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage […] - 2025-03-12 04:56:50
- Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB
- Handelsbanken Fonder AB trimmed its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,500 shares of the company’s stock after selling 1,300 shares during the period. Handelsbanken Fonder AB’s holdings […] - 2025-03-04 06:46:55
- Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Recommendation of “Buy” from Brokerages
- Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on […] - 2025-03-04 04:47:02
- Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $89.71
- Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) have been given an average rating of “Buy” by the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock […] - 2025-02-05 04:06:46
iShares MSCI World Small Cap UCITS ETF USD (Acc) APGE holdings
| Date | Number of APGE Shares Held | Base Market Value of APGE Shares | Local Market Value of APGE Shares | Change in APGE Shares Held | Change in APGE Base Value | Current Price per APGE Share Held | Previous Price per APGE Share Held |
|---|
| 2025-10-15 (Wednesday) | 16,919 | USD 944,926 | USD 944,926 | | | | |
| 2025-10-10 (Friday) | 16,814 | USD 882,231 | USD 882,231 | | | | |
| 2025-10-08 (Wednesday) | 16,814 | USD 794,293 | USD 794,293 | | | | |
| 2025-10-07 (Tuesday) | 16,814 | USD 668,020 | USD 668,020 | 72 | USD 1,354 | USD 39.73 | USD 39.82 |
| 2025-10-06 (Monday) | 16,742 | USD 666,666 | USD 666,666 | 0 | USD -1,005 | USD 39.82 | USD 39.88 |
| 2025-10-03 (Friday) | 16,742 | USD 667,671 | USD 667,671 | 0 | USD 4,520 | USD 39.88 | USD 39.61 |
| 2025-10-02 (Thursday) | 16,742 | USD 663,151 | USD 663,151 | 0 | USD 3,851 | USD 39.61 | USD 39.38 |
| 2025-10-01 (Wednesday) | 16,742 | USD 659,300 | USD 659,300 | 0 | USD -5,860 | USD 39.38 | USD 39.73 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of APGE by Blackrock for IE00BF4RFH31
Show aggregate share trades of APGE| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 72 | | | 39.730* | | 41.66 |
| 2025-09-08 | SELL | -144 | | | 38.420* | | 41.78 Profit of 6,016 on sale |
| 2025-08-15 | BUY | 70 | | | 37.290* | | 41.80 |
| 2025-08-07 | BUY | 210 | | | 36.000* | | 41.86 |
| 2025-07-29 | BUY | 70 | | | 37.930* | | 42.01 |
| 2025-07-14 | BUY | 144 | | | 38.880* | | 42.12 |
| 2025-06-30 | BUY | 140 | | | 43.430* | | 42.18 |
| 2025-06-25 | BUY | 210 | | | 42.990* | | 42.15 |
| 2025-06-20 | SELL | -36 | | | 41.960* | | 42.15 Profit of 1,517 on sale |
| 2025-06-12 | SELL | -288 | | | 41.860* | | 42.15 Profit of 12,139 on sale |
| 2025-06-02 | BUY | 108 | | | 36.330* | | 42.32 |
| 2025-05-28 | BUY | 72 | | | 36.400* | | 42.44 |
| 2025-05-14 | BUY | 36 | | | 39.850* | | 42.65 |
| 2025-05-13 | BUY | 72 | | | 39.740* | | 42.67 |
| 2025-05-07 | BUY | 108 | | | 35.240* | | 42.84 |
| 2025-04-28 | BUY | 36 | | | 37.790* | | 43.10 |
| 2025-04-16 | BUY | 468 | | | 32.040* | | 43.73 |
| 2025-04-14 | BUY | 72 | | | 33.280* | | 43.93 |
| 2025-04-08 | SELL | -72 | | | 28.790* | | 44.46 Profit of 3,201 on sale |
| 2025-04-04 | SELL | -74 | | | 32.320* | | 44.70 Profit of 3,308 on sale |
| 2025-03-28 | BUY | 360 | | | 39.720* | | 44.99 |
| 2025-03-12 | SELL | -72 | | | 38.530* | | 45.75 Profit of 3,294 on sale |
| 2025-03-04 | SELL | -74 | | | 30.370* | | 46.42 Profit of 3,435 on sale |
| 2025-02-26 | SELL | -148 | | | 31.080* | | 47.23 Profit of 6,991 on sale |
| 2025-02-13 | BUY | 38 | | | 36.260* | | 48.93 |
| 2025-02-12 | BUY | 148 | | | 35.500* | | 49.14 |
| 2025-01-27 | BUY | 36 | | | 40.220* | | 51.17 |
| 2025-01-23 | BUY | 36 | | | 40.210* | | 51.60 |
| 2024-12-09 | BUY | 1,296 | | | 49.070* | | 51.98 |
| 2024-12-04 | BUY | 72 | | | 52.020* | | 52.13 |
| 2024-12-03 | BUY | 108 | | | 46.260* | | 52.27 |
| 2024-11-19 | BUY | 216 | | | 46.520* | | 55.17 |
| 2024-11-18 | BUY | 72 | | | 45.330* | | 55.49 |
| 2024-11-12 | BUY | 140 | | | 57.350* | | 55.43 |
| 2024-11-11 | BUY | 35 | | | 60.460* | | 55.07 |
| 2024-11-11 | BUY | 35 | | | 60.460* | | 55.07 |
| 2024-11-07 | BUY | 175 | | | 58.050* | | 54.32 |
| 2024-11-07 | BUY | 175 | | | 58.050* | | 54.32 |
| 2024-10-23 | BUY | 70 | | | 51.430* | | 52.18 |
| 2024-10-23 | BUY | 70 | | | 51.430* | | 52.18 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of APGE
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 70,663 | 0 | 123,323 | 57.3% |
| 2025-09-18 | 55,220 | 0 | 144,942 | 38.1% |
| 2025-09-17 | 57,722 | 0 | 155,746 | 37.1% |
| 2025-09-16 | 43,151 | 80 | 105,790 | 40.8% |
| 2025-09-15 | 81,961 | 29 | 130,786 | 62.7% |
| 2025-09-12 | 71,051 | 0 | 214,650 | 33.1% |
| 2025-09-11 | 94,764 | 0 | 386,867 | 24.5% |
| 2025-09-10 | 59,863 | 0 | 142,028 | 42.1% |
| 2025-09-09 | 111,612 | 257 | 182,115 | 61.3% |
| 2025-09-08 | 97,038 | 0 | 179,710 | 54.0% |
| 2025-09-05 | 69,623 | 0 | 171,262 | 40.7% |
| 2025-09-04 | 53,120 | 232 | 144,344 | 36.8% |
| 2025-09-03 | 74,123 | 0 | 144,593 | 51.3% |
| 2025-09-02 | 66,515 | 4 | 129,845 | 51.2% |
| 2025-08-29 | 101,974 | 0 | 154,871 | 65.8% |
| 2025-08-28 | 59,362 | 161 | 162,552 | 36.5% |
| 2025-08-27 | 67,694 | 500 | 137,148 | 49.4% |
| 2025-08-26 | 56,467 | 12 | 108,271 | 52.2% |
| 2025-08-25 | 58,196 | 0 | 79,233 | 73.4% |
| 2025-08-22 | 156,824 | 0 | 213,083 | 73.6% |
| 2025-08-21 | 109,210 | 0 | 159,433 | 68.5% |
| 2025-08-20 | 69,720 | 0 | 118,471 | 58.8% |
| 2025-08-19 | 101,793 | 1,831 | 140,034 | 72.7% |
| 2025-08-18 | 64,930 | 0 | 92,969 | 69.8% |
| 2025-08-15 | 168,347 | 3,071 | 233,008 | 72.2% |
| 2025-08-14 | 79,489 | 519 | 209,641 | 37.9% |
| 2025-08-13 | 137,510 | 0 | 206,606 | 66.6% |
| 2025-08-12 | 98,069 | 0 | 228,509 | 42.9% |
| 2025-08-11 | 128,020 | 262 | 163,348 | 78.4% |
| 2025-08-08 | 158,402 | 0 | 252,339 | 62.8% |
| 2025-08-07 | 96,254 | 30 | 146,852 | 65.5% |
| 2025-08-06 | 183,752 | 15 | 346,213 | 53.1% |
| 2025-08-05 | 113,131 | 50 | 216,684 | 52.2% |
| 2025-08-04 | 86,042 | 0 | 161,958 | 53.1% |
| 2025-08-01 | 164,157 | 1,952 | 329,219 | 49.9% |
| 2025-07-31 | 116,400 | 0 | 253,059 | 46.0% |
| 2025-07-30 | 120,101 | 0 | 257,286 | 46.7% |
| 2025-07-29 | 131,882 | 0 | 256,505 | 51.4% |
| 2025-07-28 | 147,442 | 296 | 276,568 | 53.3% |
| 2025-07-25 | 113,974 | 0 | 225,871 | 50.5% |
| 2025-07-24 | 124,144 | 5 | 236,304 | 52.5% |
| 2025-07-23 | 85,877 | 0 | 205,618 | 41.8% |
| 2025-07-22 | 97,613 | 0 | 213,621 | 45.7% |
| 2025-07-21 | 183,752 | 60 | 441,690 | 41.6% |
| 2025-07-18 | 119,198 | 324 | 364,435 | 32.7% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.